Search Results - "Spriano, Filippo"

Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer by Bernasocchi, Tiziano, El Tekle, Geniver, Bolis, Marco, Mutti, Azzurra, Vallerga, Arianna, Brandt, Laura P., Spriano, Filippo, Svinkina, Tanya, Zoma, Marita, Ceserani, Valentina, Rinaldi, Anna, Janouskova, Hana, Bossi, Daniela, Cavalli, Manuela, Mosole, Simone, Geiger, Roger, Dong, Ze, Yang, Cai-Guang, Albino, Domenico, Rinaldi, Andrea, Schraml, Peter, Linder, Simon, Carbone, Giuseppina M., Alimonti, Andrea, Bertoni, Francesco, Moch, Holger, Carr, Steven A., Zwart, Wilbert, Kruithof-de Julio, Marianna, Rubin, Mark A., Udeshi, Namrata D., Theurillat, Jean-Philippe P.

“…Driver genes with a mutually exclusive mutation pattern across tumor genomes are thought to have overlapping roles in tumorigenesis. In contrast, we show here…”
Get full text

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy by Tarantelli, Chiara, Gaudio, Eugenio, Arribas, Alberto J, Kwee, Ivo, Hillmann, Petra, Rinaldi, Andrea, Cascione, Luciano, Spriano, Filippo, Bernasconi, Elena, Guidetti, Francesca, Carrassa, Laura, Pittau, Roberta Bordone, Beaufils, Florent, Ritschard, Reto, Rageot, Denise, Sele, Alexander, Dossena, Barbara, Rossi, Francesca Maria, Zucchetto, Antonella, Taborelli, Monica, Gattei, Valter, Rossi, Davide, Stathis, Anastasios, Stussi, Georg, Broggini, Massimo, Wymann, Matthias P, Wicki, Andreas, Zucca, Emanuele, Cmiljanovic, Vladimir, Fabbro, Doriano, Bertoni, Francesco

“…Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacologic inhibition of the PI3K/mTOR pathway has shown…”
Get full text

Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes by Barreca, Marilia, Spanò, Virginia, Montalbano, Alessandra, Cueto, Mercedes, Díaz Marrero, Ana R, Deniz, Irem, Erdoğan, Ayşegül, Lukić Bilela, Lada, Moulin, Corentin, Taffin-de-Givenchy, Elisabeth, Spriano, Filippo, Perale, Giuseppe, Mehiri, Mohamed, Rotter, Ana, P Thomas, Olivier, Barraja, Paola, Gaudêncio, Susana P, Bertoni, Francesco

“…The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique…”
Get full text

DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas by Restelli, Valentina, Lupi, Monica, Chilà, Rosaria, Vagni, Micaela, Tarantelli, Chiara, Spriano, Filippo, Gaudio, Eugenio, Bertoni, Francesco, Damia, Giovanna, Carrassa, Laura

“…The DNA damage response (DDR) kinases ATR, Chk1, and Wee1 play vital roles in the response to replication stress and in maintaining cancer genomic stability…”
Get full text

Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy by Tarantelli, Chiara, Wald, David, Munz, Nicolas, Spriano, Filippo, Bruscaggin, Alessio, Cannas, Eleonora, Cascione, Luciano, Gaudio, Eugenio, Arribas, Alberto J, Manjappa, Shivaprasad, Golino, Gaetanina, Scalise, Lorenzo, Cacciapuoti, Maria Teresa, Zucca, Emanuele, Stathis, Anastasios, Inghirami, Giorgio, Van Berkel, Patrick H, Rossi, Davide, Caimi, Paolo F, Zammarchi, Francesca, Bertoni, Francesco

“…Antibody-drug conjugates (ADCs) represent one of the most successful therapeutic approaches introduced in clinical practice in the last few years…”
Get full text

Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma by Bernasconi, Elena, Gaudio, Eugenio, Lejeune, Pascale, Tarantelli, Chiara, Cascione, Luciano, Kwee, Ivo, Spriano, Filippo, Rinaldi, Andrea, Mensah, Afua A., Chung, Elaine, Stathis, Anastasios, Siegel, Stephan, Schmees, Norbert, Ocker, Matthias, Zucca, Emanuele, Haendler, Bernard, Bertoni, Francesco

“…Summary The epigenome is often deregulated in cancer and treatment with inhibitors of bromodomain and extra‐terminal proteins, the readers of epigenetic…”
Get full text

A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers by Spriano, Filippo, Sartori, Giulio, Sgrignani, Jacopo, Barnabei, Laura, Arribas, Alberto J, Guala, Matilde, Del Amor, Ana Maria Carrasco, Tomasso, Meagan R, Tarantelli, Chiara, Cascione, Luciano, Golino, Gaetanina, Riveiro, Maria E, Bortolozzi, Roberta, Lupia, Antonio, Paduano, Francesco, Huguet, Samuel, Rezai, Keyvan, Rinaldi, Andrea, Margheriti, Francesco, Ventura, Pedro, Guarda, Greta, Costa, Giosuè, Rocca, Roberta, Furlan, Alberto, Verdonk, Luuk M, Innocenti, Paolo, Martin, Nathaniel I, Viola, Giampietro, Driessen, Christoph, Zucca, Emanuele, Stathis, Anastasios, Gahtory, Digvijay, Van den Nieuwboer, Maurits, Bornhauser, Beat, Alcaro, Stefano, Trapasso, Francesco, Cristobal, Susana, Padrick, Shae B, Pazzi, Natalina, Cavalli, Franco, Cavalli, Andrea, Gaudio, Eugenio, Bertoni, Francesco

“…Hematological cancers are among the most common cancers in adults and children. Despite significant improvements in therapies, many patients still succumb to…”
Get full text

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents by Tarantelli, Chiara, Zhang, Lu, Curti, Elisabetta, Gaudio, Eugenio, Spriano, Filippo, Priebe, Valdemar, Cascione, Luciano, Arribas, Alberto J, Zucca, Emanuele, Rossi, Davide, Stathis, Anastasios, Bertoni, Francesco

Get full text

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis by Arribas, Alberto J., Napoli, Sara, Cascione, Luciano, Sartori, Giulio, Barnabei, Laura, Gaudio, Eugenio, Tarantelli, Chiara, Mensah, Afua Adjeiwaa, Spriano, Filippo, Zucchetto, Antonella, Rossi, Francesca M, Rinaldi, Andrea, Castro de Moura, Manuel, Jovic, Sandra, Bordone-Pittau, Roberta, Di Veroli, Alessandra, Stathis, Anastasios, Cruciani, Gabriele, Stussi, Georg, Gattei, Valter, Brown, Jennifer R., Esteller, Manel, Zucca, Emanuele, Rossi, Davide, Bertoni, Francesco

“…PI3Kδ inhibitors are active in patients with lymphoid neoplasms and a first series of them have been approved for the treatment of multiple types of B-cell…”
Get full text

Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma by Napoli, Sara, Cascione, Luciano, Rinaldi, Andrea, Spriano, Filippo, Guidetti, Francesca, Zhang, Fangwen, Cacciapuoti, Maria Teresa, Mensah, Afua Adjeiwaa, Sartori, Giulio, Munz, Nicolas, Forcato, Mattia, Bicciato, Silvio, Chiappella, Annalisa, Ghione, Paola, Elemento, Olivier, Cerchietti, Leandro, Inghirami, Giorgio, Bertoni, Francesco

“…Enhancers are regulatory regions of DNA, which play a key role in cell-type specific differentiation and development. Most active enhancers are transcribed…”
Get full text

Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity by Barreca, Marilia, Spanò, Virginia, Raimondi, Maria Valeria, Tarantelli, Chiara, Spriano, Filippo, Bertoni, Francesco, Barraja, Paola, Montalbano, Alessandra

“…Because of its wide spectrum of targets and biological activities, the oxazole ring is a valuable heterocyclic scaffold in the design of new therapeutic agents…”
Get full text

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models by Gaudio, Eugenio, Tarantelli, Chiara, Spriano, Filippo, Guidetti, Francesca, Sartori, Giulio, Bordone, Roberta, Arribas, Alberto J, Cascione, Luciano, Bigioni, Mario, Merlino, Giuseppe, Fiascarelli, Alessio, Bressan, Alessandro, Mensah, Afua Adjeiwaa, Golino, Gaetanina, Lucchini, Renzo, Bernasconi, Elena, Rossi, Davide, Zucca, Emanuele, Stussi, Georg, Stathis, Anastasios, Boyd, Robert S, Dusek, Rachel L, Bisht, Arnima, Attanasio, Nickolas, Rohlff, Christian, Pellacani, Andrea, Binaschi, Monica, Bertoni, Francesco

“…Antibody drug conjugates represent an important class of anti-cancer drugs in both solid tumors and hematological cancers. Here, we report preclinical data on…”
Get full text

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models by Hicks, Stuart W, Tarantelli, Chiara, Wilhem, Alan, Gaudio, Eugenio, Li, Min, Arribas, Alberto J, Spriano, Filippo, Bordone, Roberta, Cascione, Luciano, Lai, Katharine C, Qiu, Qifeng, Taborelli, Monica, Rossi, Davide, Stussi, Georg, Zucca, Emanuele, Stathis, Anastasios, Sloss, Callum M, Bertoni, Francesco

“…Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADC targeting CD19, including…”
Get full text

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734 by Spriano, Filippo, Gaudio, Eugenio, Cascione, Luciano, Tarantelli, Chiara, Melle, Federica, Motta, Giovanna, Priebe, Valdemar, Rinaldi, Andrea, Golino, Gaetanina, Mensah, Afua Adjeiwaa, Aresu, Luca, Zucca, Emanuele, Pileri, Stefano, Witcher, Michael, Brown, Bill, Wahlestedt, Claes, Giles, Francis, Stathis, Anastasios, Bertoni, Francesco

“…Bromodomain and extra-terminal domain (BET) proteins, cyclic adenosine monophosphate response element-binding protein (CBP), and the E1A-binding protein of…”
Get full text

Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences by Barreca, Marilia, Lang, Noémie, Tarantelli, Chiara, Spriano, Filippo, Barraja, Paola, Bertoni, Francesco

“…Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies treatment, designed to provide superior efficacy and specific targeting…”
Get full text

Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma by Spriano, Filippo, Sartori, Giulio, Tarantelli, Chiara, Barreca, Marilia, Golino, Gaetanina, Rinaldi, Andrea, Napoli, Sara, Mascia, Michele, Scalise, Lorenzo, Arribas, Alberto J., Cascione, Luciano, Zucca, Emanuele, Stathis, Anastasios, Gaudio, Eugenio, Bertoni, Francesco

“…Inhibitors of the Bromo‐ and Extra‐Terminal domain (BET) family proteins have strong preclinical antitumor activity in multiple tumor models, including…”
Get full text

Targeting BET bromodomain proteins in cancer: The example of lymphomas by Spriano, Filippo, Stathis, Anastasios, Bertoni, Francesco

“…The Bromo- and Extra-Terminal domain (BET) family proteins act as “readers” of acetylated histones and they are important transcription regulators. BRD2, BRD3,…”
Get full text

Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents by Spriano, Filippo, Tarantelli, Chiara, Cascione, Luciano, Gaudio, Eugenio, Golino, Gaetanina, Scalise, Lorenzo, Cacciapuoti, Maria Teresa, Zucca, Emanuele, Stathis, Anastasios, Van Berkel, Patrick H, Inghirami, Giorgio, Zammarchi, Francesca, Bertoni, Francesco

“…Camidanlumab tesirine (ADCT-301) is a CD25-specific antibody-drug conjugate (ADC) employing SG3199, a highly cytotoxic DNA minor groove cross-linking…”
Get full text

Abstract P073: Pharmacological inhibition of IRAK4 with CA-4948 is beneficial in marginal zone lymphoma models with secondary resistance to PI3K and BTK inhibitors by Guidetti, Francesca, Arribas, Alberto J., Spriano, Filippo, Barnabei, Laura, von Roemeling, Reinhard, Martinez, Elizabeth, Zucca, Emanuele, Bertoni, Francesco

“…Abstract Background. Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy for which no standard treatment exists. B-cell receptor (BCR) signaling…”
Get full text

Abstract B009: The histone deacetylase inhibitor pracinostat and its metabolite SB991 are active as single agents and in combination with 5-azacitidine in acute myeloid leukemia cells by Mensah, Afua Adjeiwaa, Spriano, Filippo, Gaudio, Eugenio, Bonifacio, Annalisa, Lovati, Emanuela, Pietra, Claudio, Bertoni, Francesco

“…Abstract Background: Pracinostat (SB939) is a class I, II and IV histone deacetylase inhibitor (HDACi), currently in phase 3 in combination with azacitidine…”
Get full text